Peter Bober1, Michal Alexovič1, Zuzana Tomková1, Róbert Kilík2, Ján Sabo1. 1. Department of Medical and Clinical Biophysics, Faculty of Medicine, University of P.J. Šafárik in Košice, Trieda SNP1, 04011 Košice, Slovakia. 2. 1st Department of Surgery, Faculty of Medicine, University of P.J. Šafárik in Košice, Trieda SNP1, 04011 Košice, Slovakia.
Abstract
BACKGROUND: Transforming RhoA proteins (RHOA) and their downstream Diaphanous homolog 1 proteins (DIAPH1) or mDia1 participate in the regulation of actin cytoskeleton which plays critical role in cells, i.e., morphologic changes and apoptosis. METHODOLOGY: To determine the cell viability the real time cell analysis (RTCA) and flow cytometry were used. To perform proteomic analysis, the label-free quantitative method and post-translation modification by the nano-HPLC and ESI-MS ion trap mass analyser were used. RESULTS: The results of the cell viability showed an increase of dead cells (around 30 %) in MCF-7/DOX-1 (i.e., 1μM of doxorubicin was added to MCF-7/WT breast cancer cell line) compared to MCF-7/WT (control) after 24 h doxorubicin (DOX) treatment. The signalling pathway of the Regulation of actin cytoskeleton (p<0.0026) was determined, where RHOA and mDia1 proteins were up-regulated. Also, post-translational modification analysis of these proteins in MCF-7/DOX-1 cells revealed dysregulation of the actin cytoskeleton, specifically the collapse of actin stress fibbers due to phosphorylation of RHOA at serine 188 and mDia1 at serine 22, resulting in their deactivation and cell apoptosis. CONCLUSION: These results pointed to an assumed role of DOX to dysregulation of actin cytoskeleton and cell death.
BACKGROUND: Transforming RhoA proteins (RHOA) and their downstream Diaphanous homolog 1 proteins (DIAPH1) or mDia1 participate in the regulation of actin cytoskeleton which plays critical role in cells, i.e., morphologic changes and apoptosis. METHODOLOGY: To determine the cell viability the real time cell analysis (RTCA) and flow cytometry were used. To perform proteomic analysis, the label-free quantitative method and post-translation modification by the nano-HPLC and ESI-MS ion trap mass analyser were used. RESULTS: The results of the cell viability showed an increase of dead cells (around 30 %) in MCF-7/DOX-1 (i.e., 1μM of doxorubicin was added to MCF-7/WT breast cancer cell line) compared to MCF-7/WT (control) after 24 h doxorubicin (DOX) treatment. The signalling pathway of the Regulation of actin cytoskeleton (p<0.0026) was determined, where RHOA and mDia1 proteins were up-regulated. Also, post-translational modification analysis of these proteins in MCF-7/DOX-1 cells revealed dysregulation of the actin cytoskeleton, specifically the collapse of actin stress fibbers due to phosphorylation of RHOA at serine 188 and mDia1 at serine 22, resulting in their deactivation and cell apoptosis. CONCLUSION: These results pointed to an assumed role of DOX to dysregulation of actin cytoskeleton and cell death.
Authors: N Watanabe; P Madaule; T Reid; T Ishizaki; G Watanabe; A Kakizuka; Y Saito; K Nakao; B M Jockusch; S Narumiya Journal: EMBO J Date: 1997-06-02 Impact factor: 11.598
Authors: Kirsten J M Schimmel; Dick J Richel; Renée B A van den Brink; Henk-Jan Guchelaar Journal: Cancer Treat Rev Date: 2004-04 Impact factor: 12.111
Authors: Mónica C García; Nabila Naitlho; José Manuel Calderón-Montaño; Estrella Drago; Manuela Rueda; Marcela Longhi; Antonio M Rabasco; Miguel López-Lázaro; Francisco Prieto-Dapena; María Luisa González-Rodríguez Journal: Pharmaceutics Date: 2021-06-27 Impact factor: 6.321
Authors: Rebeca Carrión-Marchante; Valerio Frezza; Ana Salgado-Figueroa; M Isabel Pérez-Morgado; M Elena Martín; Víctor M González Journal: Pharmaceuticals (Basel) Date: 2021-05-17